{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:01:12Z","timestamp":1787799672432,"version":"build-2784847793"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) represents a highly aggressive subtype of breast cancer characterized by increased recurrence rates and poor prognosis, primarily due to the lack of effective therapeutic targets. Pseudouridine synthases (PUSs) are a class of enzymes that are responsible for catalyzing the isomerization of uridine to pseudouridine in RNA, thereby contributing to cancer progression. In the present study, we examined the roles of PUSs in modulating the biological properties of TNBC using bioinformatics and experimental investigations. Increased gene expression levels of PUSs, particularly PUS7, were identified in TNBC tissues from the TCGA RNA-seq dataset and were found to be associated with unfavorable survival of TNBC patients. In addition, increased protein levels of PUS7 were identified in TNBC patient tissues and cell lines compared with non-TNBC. The increased PUS7 expression was in line with the stemness of TNBC cells. Knockdown of PUS7 in MDA-MB-231 and MDA-MB-468 cells inhibited stemness, migration, and colony formation. Transfection with a PUS7-Mut construct, which eliminated the enzymatic activity of PUS7, reversed the stimulating effects of PUS7 on stemness, migration, and colony formation in TNBC cells. This study highlights the influence of PUS7 on the biological properties of TNBC through its enzymatic activity, providing valuable insights and potential avenues for the identification of effective therapeutic targets for TNBC.<\/jats:p>","DOI":"10.1038\/s41598-025-25684-z","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:06:59Z","timestamp":1768813619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The pseudouridine synthase PUS7 is associated with stemness and represents a potential therapeutic target in triple-negative breast cancer cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Lu","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangchun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"25684_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"25684_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L., Duan, J. J., Bian, X. W. & Yu, S. C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22, 61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5 (2020).","journal-title":"Breast Cancer Res."},{"key":"25684_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91\u2013113. https:\/\/doi.org\/10.1038\/s41571-021-00565-2 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"25684_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan, T. E. & Tolaney, S. M. Role of immunotherapy in triple-negative breast cancer. J. Natl. Compr. Canc. Netw. 18, 479\u2013489. https:\/\/doi.org\/10.6004\/jnccn.2020.7554 (2020).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"25684_CR5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9 (2020).","journal-title":"Lancet"},{"key":"25684_CR6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","volume":"169","author":"IA Roundtree","year":"2017","unstructured":"Roundtree, I. A., Evans, M. E., Pan, T. & He, C. Dynamic RNA modifications in gene expression regulation. Cell 169, 1187\u20131200. https:\/\/doi.org\/10.1016\/j.cell.2017.05.045 (2017).","journal-title":"Cell"},{"key":"25684_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.trecan.2017.02.004","volume":"3","author":"F Rapino","year":"2017","unstructured":"Rapino, F., Delaunay, S., Zhou, Z., Chariot, A. & Close, P. tRNA Modification: Is cancer having a wobble?. Trends Cancer 3, 249\u2013252. https:\/\/doi.org\/10.1016\/j.trecan.2017.02.004 (2017).","journal-title":"Trends Cancer"},{"key":"25684_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41419-017-0129-x","volume":"9","author":"D Dai","year":"2018","unstructured":"Dai, D., Wang, H., Zhu, L., Jin, H. & Wang, X. N6-methyladenosine links RNA metabolism to cancer progression. Cell Death Dis. 9, 124. https:\/\/doi.org\/10.1038\/s41419-017-0129-x (2018).","journal-title":"Cell Death Dis."},{"key":"25684_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nature13802","volume":"515","author":"TM Carlile","year":"2014","unstructured":"Carlile, T. M. et al. Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and human cells. Nature 515, 143\u2013146. https:\/\/doi.org\/10.1038\/nature13802 (2014).","journal-title":"Nature"},{"key":"25684_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/15476286.2016.1276150","volume":"14","author":"AC Rintala-Dempsey","year":"2017","unstructured":"Rintala-Dempsey, A. C. & Kothe, U. Eukaryotic stand-alone pseudouridine synthases\u2014RNA modifying enzymes and emerging regulators of gene expression?. RNA Biol 14, 1185\u20131196. https:\/\/doi.org\/10.1080\/15476286.2016.1276150 (2017).","journal-title":"RNA Biol"},{"key":"25684_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-genet-112618-043830","volume":"54","author":"EK Borchardt","year":"2020","unstructured":"Borchardt, E. K., Martinez, N. M. & Gilbert, W. V. Regulation and function of RNA pseudouridylation in human cells. Annu. Rev. Genet. 54, 309\u2013336. https:\/\/doi.org\/10.1146\/annurev-genet-112618-043830 (2020).","journal-title":"Annu. Rev. Genet."},{"key":"25684_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrm4040","volume":"16","author":"J Karijolich","year":"2015","unstructured":"Karijolich, J., Yi, C. & Yu, Y. T. Transcriptome-wide dynamics of RNA pseudouridylation. Nat. Rev. Mol. Cell Biol. 16, 581\u2013585. https:\/\/doi.org\/10.1038\/nrm4040 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"25684_CR13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.tips.2021.10.002","volume":"42","author":"DY Zhang","year":"2021","unstructured":"Zhang, D. Y., Ming, G. L. & Song, H. PUS7: A targetable epitranscriptomic regulator of glioblastoma growth. Trends Pharmacol. Sci. 42, 976\u2013978. https:\/\/doi.org\/10.1016\/j.tips.2021.10.002 (2021).","journal-title":"Trends Pharmacol. Sci."},{"key":"25684_CR14","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1126\/science.aad8711","volume":"352","author":"WV Gilbert","year":"2016","unstructured":"Gilbert, W. V., Bell, T. A. & Schaening, C. Messenger RNA modifications: Form, distribution, and function. Science 352, 1408\u20131412. https:\/\/doi.org\/10.1126\/science.aad8711 (2016).","journal-title":"Science"},{"key":"25684_CR15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s43018-021-00238-0","volume":"2","author":"Q Cui","year":"2021","unstructured":"Cui, Q. et al. Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis. Nat. Cancer 2, 932\u2013949. https:\/\/doi.org\/10.1038\/s43018-021-00238-0 (2021).","journal-title":"Nat. Cancer"},{"key":"25684_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13046-021-01951-5","volume":"40","author":"D Song","year":"2021","unstructured":"Song, D. et al. HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance. J. Exp. Clin. Cancer Res. 40, 170. https:\/\/doi.org\/10.1186\/s13046-021-01951-5 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"25684_CR17","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/biology10111130","volume":"10","author":"H Li","year":"2021","unstructured":"Li, H. et al. The identification of RNA modification gene PUS7 as a potential biomarker of ovarian cancer. Biology 10, 1130. https:\/\/doi.org\/10.3390\/biology10111130 (2021).","journal-title":"Biology"},{"key":"25684_CR18","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.7150\/ijbs.94058","volume":"20","author":"C Zheng","year":"2024","unstructured":"Zheng, C. et al. Dysregulated ribosome biogenesis is a targetable vulnerability in triple-negative breast cancer: MRPS27 as a key mediator of the stemness-inhibitory effect of lovastatin. Int. J. Biol. Sci. 20, 2130\u20132148. https:\/\/doi.org\/10.7150\/ijbs.94058 (2024).","journal-title":"Int. J. Biol. Sci."},{"key":"25684_CR19","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/ijms23031665","volume":"23","author":"P Ferrari","year":"2022","unstructured":"Ferrari, P. et al. Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC. Int. J. Mol. Sci. 23, 1665. https:\/\/doi.org\/10.3390\/ijms23031665 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"25684_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","volume":"31","author":"YZ Jiang","year":"2021","unstructured":"Jiang, Y. Z. et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: The FUTURE trial. Cell Res 31, 178\u2013186. https:\/\/doi.org\/10.1038\/s41422-020-0375-9 (2021).","journal-title":"Cell Res"},{"key":"25684_CR21","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang, Y. Z. et al. Genomic and transcriptomic landscape of triple-negative breast cancers: Subtypes and treatment strategies. Cancer Cell 35, 428\u2013440. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.001 (2019).","journal-title":"Cancer Cell"},{"key":"25684_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41422-023-00795-2","volume":"33","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. Cell Res. 33, 389\u2013402. https:\/\/doi.org\/10.1038\/s41422-023-00795-2 (2023).","journal-title":"Cell Res."},{"key":"25684_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","volume":"35","author":"F Yang","year":"2023","unstructured":"Yang, F. et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 35, 84\u2013100. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.021 (2023).","journal-title":"Cell Metab."},{"key":"25684_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1470-2045(23)00579-X","volume":"25","author":"L Fan","year":"2024","unstructured":"Fan, L. et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): A multi-cohort, randomised, phase 2 trial. Lancet Oncol. 25, 184\u2013197. https:\/\/doi.org\/10.1016\/S1470-2045(23)00579-X (2024).","journal-title":"Lancet Oncol."},{"key":"25684_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1787","volume":"14","author":"X Rao","year":"2024","unstructured":"Rao, X. et al. Integrating radiosensitivity index and triple-negative breast cancer subtypes reveals SERPINB5 as a radioresistance biomarker in triple-negative breast cancer. Clin. Transl. Med. 14, e1787. https:\/\/doi.org\/10.1002\/ctm2.1787 (2024).","journal-title":"Clin. Transl. Med."},{"key":"25684_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413103","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Dual inhibition of CDK4\/6 and CDK7 suppresses triple-negative breast cancer progression via epigenetic modulation of SREBP1-regulated cholesterol metabolism. Adv. Sci. https:\/\/doi.org\/10.1002\/advs.202413103 (2024).","journal-title":"Adv. Sci."},{"key":"25684_CR27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.cell.2018.06.046","volume":"174","author":"V Davalos","year":"2018","unstructured":"Davalos, V., Blanco, S. & Esteller, M. SnapShot: Messenger RNA modifications. Cell 174, 498\u2013498. https:\/\/doi.org\/10.1016\/j.cell.2018.06.046 (2018).","journal-title":"Cell"},{"key":"25684_CR28","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1261\/rna.063503.117","volume":"23","author":"N Jonkhout","year":"2017","unstructured":"Jonkhout, N. et al. The RNA modification landscape in human disease. RNA 23, 1754\u20131769. https:\/\/doi.org\/10.1261\/rna.063503.117 (2017).","journal-title":"RNA"},{"key":"25684_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/02841869509093640","volume":"34","author":"T Rasmuson","year":"1995","unstructured":"Rasmuson, T. & Bjork, G. R. Urinary excretion of pseudouridine and prognosis of patients with malignant lymphoma. Acta Oncol. 34, 61\u201367. https:\/\/doi.org\/10.3109\/02841869509093640 (1995).","journal-title":"Acta Oncol."},{"key":"25684_CR30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/mc.23473","volume":"62","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. PUS7 promotes the proliferation of colorectal cancer cells by directly stabilizing SIRT1 to activate the Wnt\/beta-catenin pathway. Mol. Carcinog. 62, 160\u2013173. https:\/\/doi.org\/10.1002\/mc.23473 (2023).","journal-title":"Mol. Carcinog."},{"key":"25684_CR31","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1007\/s10620-021-06936-0","volume":"67","author":"J Du","year":"2022","unstructured":"Du, J., Gong, A., Zhao, X. & Wang, G. Pseudouridylate synthase 7 promotes cell proliferation and invasion in colon cancer through activating PI3K\/AKT\/mTOR signaling pathway. Dig. Dis. Sci. 67, 1260\u20131270. https:\/\/doi.org\/10.1007\/s10620-021-06936-0 (2022).","journal-title":"Dig. Dis. Sci."},{"key":"25684_CR32","doi-asserted-by":"publisher","first-page":"769280","DOI":"10.3389\/fonc.2021.769280","volume":"11","author":"G Barchiesi","year":"2021","unstructured":"Barchiesi, G. et al. Emerging role of PARP inhibitors in metastatic triple negative breast cancer. Current scenario and future perspectives. Front. Oncol. 11, 769280. https:\/\/doi.org\/10.3389\/fonc.2021.769280 (2021).","journal-title":"Front. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25684-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:08:48Z","timestamp":1769213328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25684-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["25684"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25684-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2411"}}